drugset / Trial / NCT07443592
Treatment for Ph-negative ALL for Adults up to 65 Years
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this trial is to provide a protocol for treatment for adults with Ph-negative acute lymphoblastic leukemia (ALL) and to learn if this provides higher probability of survival than the previous one. The main question is to know if the incorporation of blinatumomab for B-cell precursor ALL, substituting some chemotherapy blocks, offers better probability of survival than the previous trial, which did not use immunotherapy. In addition, T-cell precursor ALL participants will receive different treatment approaches depending on the stage of maturation of the tumor.
Timeline
- Start
- 2026-03-06
- Primary completion
- 2031-03-06
- Completion
- 2033-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Daunorubicin | Small molecule | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Idarubicin | Small molecule | — | — |
| Subject | Inotuzumab | Other / unclassified | — | — |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Pegylated asparaginase | Unknown | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Vincristine | Small molecule | — | — |